Duke University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Duke University sits in the top decile of US sponsors by registered trial count (#9 of 15,742 sponsors by registered trial count).
Duke University: 1,725 sponsored US clinical trials, 187 recruiting.
Duke University sponsors 1,725 registered US clinical trials on ClinicalTrials.gov, 187 of them currently recruiting, and 1,244 completed. 175 of these trials are in Phase 3-4 (later-stage) and 311 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 15 trials.
Top-decile sponsor footprint
Duke University ranks in the top decile of sponsors by registered trial count (#9 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,244 of 1,444 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,725 total, page 25 of 35
Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT)
NCT01800968
Comparative Study of Polymetric Clips (Hem-o-Lok) Versus Historical Endoscopic Staplers for Laparoscopic Appendectomy
NCT01830387
Southeastern Diabetes Initiative Clinical Intervention
NCT01965639
Translational Research Evaluating Neurocognitive Memory Processes
NCT01834677
Study on Visual Function Impairments in Dry Age-related Macular Degeneration
NCT01822873
Postoperative Subtenons Anesthesia for Postoperative Pain in Pediatric Strabismus Surgery
NCT01812044
Pelvic Ring Injury
NCT01821339
Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)
NCT01820754
Drug-Related Problems and Healthcare Utilization Post-Hospital Discharge
NCT01806038
PLATFORM to Maximize Patient Knowledge of Health Goals After Acute Myocardial Infarction
NCT01807208
Safety Study of Aztreonam Lysine for Inhalation (AZLI) in the Treatment of Early Bronchiolitis Obliterans Syndrome (BOS)
NCT01469364
Combination Bupropion / Varenicline for Smoking Cessation in Male Smokers
NCT01806779
The Role of S-nitrosohemoglobin in Regulating Systemic Blood Flow During Hypoxia and Normoxia
NCT01905696
Mechanistic Assessment of the Properties of Saxagliptin in Subjects Undergoing Coronary Artery Bypass Graft Surgery
NCT01765270
Effects of Sildenafil on Choroidal Thickness in AMD
NCT01830790
Carolina Alcohol and Drug Resources
NCT01791179
Dietary Nitrate and Exercise to Augment Exercise Training Benefits in Subjects With DM+PAD
NCT01785524
Pilot Testing a Patient and Provider Intervention for Managing Osteoarthritis in Hispanic Adults.
NCT01782417
Microvascular and Fibrosis Imaging Study
NCT01758250
Ultrasound in Muscle Biopsy
NCT01790178
Neuromuscular Ultrasound in ALS
NCT01785550
Total Knee Arthroplasty: Functional and Clinical Outcomes
NCT01811563
Contingency Management for Smoking Cessation in Homeless Smokers
NCT01789710
Characterizing and Comparing the Profile of Microorganisms From Specific Body Sites and Environmental Surfaces in Newly Disinfected Patient Rooms
NCT01803100
Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients
NCT01738646
Immediate vs. Delayed Postpartum Etonogestrel Implant
NCT01767285
Optical Imaging and User Perception Study of Vaginal Gel
NCT01716000
High Yield Intraoperative, Autologous Platelet Apheresis
NCT01819246
Bevacizumab Beyond Progression (BBP)
NCT01740258
Serial Collection of Primary Progressive Multiple Sclerosis Participants in the MURDOCK Study
NCT01776060
Hypercapnia: Cognitive Effects and Monitoring
NCT01782625
Improving Decision Making for Patients With Prolonged Mechanical Ventilation
NCT01751061
Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma
NCT01729338
Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) to Three Different Dose Initiation Strategies With Vilazodone
NCT02015546
Pharmacogenetic Testing in Primary Care
NCT01600846
Physiologic Mechanisms in Pediatric Traumatic Brain Injury (TBI)
NCT01763892
Dexamethasone for Post-cesarean Delivery Pain
NCT01812057
Environments as Smoking Cues: Imaging Brain Substrates, Developing New Treatments (CameraCue)
NCT01840111
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment
NCT01685840
Incisional Negative Pressure Wound Therapy
NCT01759381
Ranolazine for the Treatment of Chest Pain in HCM Patients
NCT01721967
Exploring Massage Benefits for Arthritis of the Knee for VA Healthcare Users
NCT01714869
Symptom Clusters in Children With Leukemia
NCT01708421
Exploring Beliefs and Behaviors About Weight Loss in Couples
NCT01777711
Cognitive Rehabilitation in Sickle Cell Disease
NCT01793740
iCare vs Tonopen vs Goldmann Applanation Post-vitrectomy Surgery
NCT01786954
Transplantation and the Use of Raltegravir in HIV-Infected Patients
NCT01793467
Antidepressant Plus Asenapine Versus Antidepressant Plus Placebo for Depression
NCT01670019
Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure
NCT01644331
Integrative Coping Group for Children
NCT01813669
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 136 |
| Phase 2 | 175 |
| Phase 3 | 41 |
| Phase 4 | 134 |
Therapeutic Areas
What is open in the Duke University pipeline
187 recruiting of 1,725 indexed (11% open); 1,244 completed (72%).
Phase mix: 175 late (III/IV) vs 311 early (I/II) (early-phase heavy).
Top condition: Obesity (15 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Duke University: open-pipeline peers nationwide
Peers matched on 1,725 registered trials and 11% open enrollment, not the therapeutic-area sidebar.
Duke University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,725 trials (± recruiting share)
- University of California, San Francisco · 1,713 trials · 16% recruiting
- Stanford University · 1,744 trials · 15% recruiting
- VA Office of Research and Development · 1,668 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
Sponsors near 11% open enrollment (± trial volume)
- Carnegie Mellon University · 11% recruiting · 37 trials
- CAMC Health System · 11% recruiting · 28 trials
- UConn Health · 11% recruiting · 178 trials
- Hartford Hospital · 11% recruiting · 75 trials
Related
What to do with this Duke University page
1,725 registered trials is a research-attention snapshot, not an endorsement of Duke University or any single study.
- 187 of Duke University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition Duke University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Duke University pipeline card: 1,725 registered trials from official public datasets.Report a data error.